California will not renew $54 million contract with Walgreens over abortion pill policy

California will not renew  million contract with Walgreens over abortion pill policy


A Walgreens store in San Francisco, California, US, on Tuesday, March 7, 2023.

David Paul Morris | Bloomberg | Getty Images

California will not renew a $54 million contract with Walgreens over the drug store chain’s decision not to sell the abortion pill in some states due to legal restrictions.

“California will not stand by as corporations cave to extremists and cut off critical access to reproductive care and freedom,” Gov. Gavin Newsom said in a statement Wednesday. “California is on track to be the fourth largest economy in the world and we will leverage our market power to defend the right to choose.”

Newsom said on Monday that the state was “done” doing business with Walgreens. California used the contract to buy specialty prescription drugs for the prison system. The state is reviewing all of its business contracts with Walgreens.

Walgreens said it will sell the abortion pill, mifepristone, in any state where it is “legally permissible to do so.” Republican attorneys general in 21 states warned Walgreens in February that selling or distributing the abortion pill in their states would violate local laws.

The drug store chain told them it would not sell or mail mifepristone in their states.

The Food and Drug Administration in January allowed retail pharmacies like Walgreens to sell mifepristone so long as they become certified under an agency program that monitors how the pill is used and distributed. Walgreens and CVS have said they plan to become certified under that program.

At least 12 states have banned abortion since the Supreme Court overturned Roe v. Wade last year. Several other states have tighter restrictions on mifepristone than the FDA does.

Walgreens is also not selling the abortion pill in states like Alaska, Kansas or Montana where abortion is protected as a right under the states’ constitutions. The drug store will also not sell mifepristone in Iowa, where the state Supreme Court last year overturned state constitutional protections for abortion.

Alaska requires patients to get the pill from a doctor. In Kansas, the state had required patients to obtain the abortion pill in person from a physician, but a state court blocked that law in November. Montana’s requirement that patients visit a doctor to get mifepristone is also temporarily blocked by a court.

Join CNBC’s Healthy Returns on March 29th, where we’ll convene a virtual gathering of CEOs, scientists, investors and innovators in the health care space to reflect on the progress made today to reinvent the future of medicine. Plus, we’ll have an exclusive rundown of the best investment opportunities in biopharma, health-tech and managed care. Learn more and register today: http://bit.ly/3DUNbRo

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

Abortion pill makers brace for restrictions a year after Trump’s election
Health

Abortion pill makers brace for restrictions a year after Trump’s election

Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois. Erin Hooley | Chicago Tribune | Tribune News Service | Getty Images Just over a year since Donald Trump was elected president again, the $6.9 billion abortion pill industry is operating under the same federal rules he inherited from former President Joe […]

Read More
Republicans push Obamacare tax credit alternatives as enrollment deadline looms
Health

Republicans push Obamacare tax credit alternatives as enrollment deadline looms

An Obamacare sign is displayed outside an insurance agency on Nov. 12, 2025 in Miami, Florida. Joe Raedle | Getty Images With enhanced Obamacare tax credits set to expire at the end of the year, Republicans are proposing new alternatives aimed at lowering the cost of health care. Their window for doing so is rapidly […]

Read More
Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target
Health

Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target

The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the […]

Read More